Maxim Group analyst Caroline Palomeque maintained a Buy rating on Brainstorm Cell Therapeutics (NASDAQ: BCLI) today and set a price target of $9. The company’s shares opened today at $4.02.
Palomeque said:
“BrainStorm announced that the Office (USPTO) granted a new US patent titled “Methods of Neurotrophic Factors”. The allowed claims for the patent cover the method for generating NurOwn (MSC-NTF cells) in industrial amounts for clinical practice.”
According to TipRanks.com, Palomeque is a 1-star analyst with an average return of -4.0% and a 35.8% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
Currently, the analyst consensus on Brainstorm Cell Therapeutics is a Moderate Buy with an average price target of $10.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.35 and a one-year low of $2.88. Currently, Brainstorm Cell Therapeutics has an average volume of 72.75K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
